Elevate Medical Affairs Podcast Channel

MAPS speaks with Tim Mikelhashvili and winners of his Medical Affairs Innovation Olympics about applications that can match patients with clinical trials and provide real-time input to provide context for clinical decisions.

When we think about Medical Insights, the first function that comes to mind is Field Medical and capturing/analyzing MSL/HCP interactions in ways that lead to strategic actions. But there are other sources of insights, including the Medical Information function. Many organizations are already capturing and quantifying MedInfo requests to learn more about the types of questions HCPs are asking. Now tools exist to look deeper into this data, allowing MedInfo teams to truly contribute to the generation, analysis of Medical Insights. Learn more in this episode of the MAPS podcast series, Elevate.

On today's episode, we're Speaking with Tim Mikhelashvili, CEO and Co-Founder of Amedea Pharma, and the winners of his Medical Affairs Olympics Competition who dared to come together to share ideas across MA functions.This podcast is sponsored by Amedea Pharma.

This series of the Elevate Podcast illuminates the path scientific communication takes from teaching to diagnosis to treating all the way to changing, prolonging, and saving patient lives. External Education of a growing variety of stakeholders in healthcare by the Medical Affairs Division of Pharma and Medical Device industry reflects the critical role Education in Medicine plays in our Age of Information. The podcast features critical discussions with leading educators across healthcare from the various perspectives of pharma / biotech sponsors, program organizers, attendees, and patients with a quest to explore some of the most novel, intriguing formats of Medical Education, following their approaches to learning in our digital age as well as their current gaps or success stories. The goal of the podcast is to make medical education simpler to access, more relevant to apply across healthcare organizations, and more continuous to inspire innovation and quality.This is a first of a series of episodes that examines the podcast as one of the most effective emerging channels and formats of education in medicine. Our host, Tim Mikhelashvili, PharmD, Co-Founder and CEO of Amedea Pharma and Chair of the Mentorship Program at the Medical Affairs Professional Society (MAPS) speaks with Shelby Englert, Vice President of Education at the American Urological Association to learn why podcasts are powerful from a Professional Medical Society’s perspective. Shelby explains why its organization started its AUA University podcast, now with 165 episodes and the role it has played in building and growing its community of urologists in the association. She also describes how the AUA University podcast is structured, how it has evolved over time, and shares personal suggestions for elements of education most valuable and relevant to an audience in a podcast, providing specific examples that demonstrate the direct impact of the podcast on patient and physician behaviors as well as health outcomes. Listen to this episode because it not only centers on the ultimate impact of podcasts on the quality of medical education, but also discusses all the “supporting players” and “accessories” to the podcast required such as channels, technology, and timing of podcast communication to make a podcast successful and valuable in healthcare.

How do you deliver impactful medical education? Hear from industry experts how to design medical education programs successfully for today’s healthcare professionals, in our latest podcast episode, sponsored by Wiley.

In today's episode, we're talking with Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1 about Artificial Intelligence — specifically about how AI can accelerate diagnosis and treatment. This episode is sponsored by OM1.

Today we're talking about publications impact with Mike Taylor, Head of Data Insights and GRONYA Farrell, Manager Corporate Life Science, Central Europe, both at Digital Science. We'll discuss the questions:Where are we now?Are we looking beyond impact factor? And how to do we make sense of the data and translate "numbers" into "actionable insights". This episode is sponsored by Digital Science, choosing journals and understanding publication impact in the digital age.

Post-approval safety studies have traditionally been cumbersome and expensive, and safety study sites are likely to mirror those used in clinical trials, leading organizations to potentially miss safety signals in populations beyond those that typically participate at trial sites. Here we speak with Stefan C. Weiss, MD, Managing Director, Dermatology at OM1 about a transformation in the way we conduct safety studies — relying on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety.

As technology changes the ways we engage with external stakeholders, the skills we need to manage these interactions are changing, as well. Here we speak with Jen Millard, Vice President of Field Medical at IQVIA, about emerging competencies for external engagement. This episode is sponsored by IQVIA. 

Patient communities continue to mobilize and play an increasingly important role by influencing many elements of the drug development journey and subsequent patient access and support activities. This input ranges from natural history studies, recruitment in clinical trials, understanding burden, contributing to Health Technology Assessments and co-creating educational resources that enable shared decision making and adherence support. Given Medical Affairs stakeholders have similar reach across drug development and commercialization it is logical that this function plays a central role in an organization’s patient-first thinking and strategy. To achieve this, Medical Affairs stakeholders will need to develop thoughtful and impactful strategies that not only build the trust of patient communities but also their internal colleagues.  Here we discuss patient-centricity strategies and actions with Gavin Jones, Global Advisor Rare Disease, OPEN Health, Jenny Ghith, Senior Director, Omnichannel Strategy and Innovations Lead, Pfizer, and Brittany Wolf, Director, Patient Centricity Lead, Pfizer.